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2Abstract38
Background 39
Numerous randomised trials have confirmed the efficacy of medical expulsive therapy with 40
tamsulosin in patients with distal ureteral stones. However, to date, no randomised, double-41
blind, placebo-controlled trials have been performed. 42
Objective43
The objective of this trial was to evaluate the efficacy of medical expulsive therapy with 44
tamsulosin in a randomised, double-blind, placebo-controlled setting.45
Design, Setting, and Participants46
Patients presenting with single distal ureteral stones ≤7mm were included in this trial.47
Intervention48
Patients were randomised in a double-blind fashion to receive either tamsulosin or placebo 49
for 21 days. The medication was discontinued either after stone expulsion or intervention. 50
Abdominal computed tomography was performed to assess the initial and final stone status.51
Measurements52
The primary endpoint was the stone expulsion rate. Secondary endpoints were time to stone 53
passage, the amount of analgesics required, the maximum daily pain-score, safety of the 54
therapy and the intervention rate.55
Results and Limitations56
Ten out of 100 randomised patients were excluded from the analysis. No statistically 57
significant differences were found between the two treatment arms in patient characteristics 58
and stone size (median 4.1mm (tamsulosin arm) vs. 3.8mm (placebo arm), p=0.3). The stone 59
expulsion rate was not significantly different between the tamsulosin arm (86.7%) and 60
placebo arm (88.9%; p=1.0). Median time to stone passage was 7 days in the tamsulosin arm 61
and 10 days in the placebo arm (logrank p=0.36). Patients in the tamsulosin arm required 62
significantly less analgesics than patients in the placebo arm (median 3 vs. 7 analgesics, 63
3p=0.011). A caveat is that the exact time of stone passage was missing in 29 patients. 64
Conclusions65
Tamsulosin treatment does not improve the stone expulsion rate in patients with distal 66
ureteral stones ≤7mm. Nevertheless, patients may benefit from a supportive analgesic effect. 67
Clinicaltrials.gov #: NCT0083170168
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4Introduction 90
Current therapeutic options for ureteral stones include active intervention as well as 91
conservative “watch and wait” approaches. Endoscopic treatment of ureteral stones has a 92
high success rate and reliably results in immediate stone removal [1, 2]. However, surgical as 93
well as anaesthetic risks are not negligible and serious complications, albeit rare, are possible 94
[3]. Thus, for many patients, a conservative treatment without invasive procedures is an 95
appealing option. Watchful waiting, however, not always results in stone clearance and may 96
be associated with recurrent renal colic [4]. Once a conservative approach proves 97
unsuccessful, interventional treatment becomes necessary. After a period of conservative 98
treatment this is often inefficient or has a higher risk for complications due to stone 99
impaction and the associated inflammatory reaction of the ureter [5, 6]. 100
The therapeutic potential of alpha-blockers for ureteral stone disease has been investigated 101
prompted by the detection of alpha-receptors in ureteral smooth muscle cells [7]. Successful 102
medical expulsive therapy (MET) for patients with distal ureteral stones using the non-103
selective alpha-blocker doxazosine was first reported in the late 1990’s [8]. Since then, 104
numerous clinical trials were performed to investigate the efficacy of MET using the 1a/d 105
selective alpha-blocker tamsulosin alone and in combination with other drugs like 106
corticosteroids and antibiotics [9-18]. Most of these studies were randomised and revealed 107
that tamsulosin treatment significantly improves the expulsion rate of medium-sized (3-108
10mm) distal ureteral stones. Thus, tamsulosin represents a non-invasive and cost-effective 109
alternative to interventional approaches [19]. However, none of the studies were performed in 110
a double-blind, placebo-controlled fashion.111
The objective of this trial was to evaluate the efficacy of MET with tamsulosin for ureteral 112
stones ≤7mm in a randomised, double-blind, placebo-controlled setting.113
114
115
5Material and Methods116
Participants: This randomised, double-blind, placebo-controlled trial was performed in the 117
Department of Urology, University Hospital of Zürich with subjects in an outpatient setting. 118
All male and female patients 18 years or older presenting with acute renal colic were 119
evaluated for study participation. Patients with a single ureteral stone ≤7mm below the 120
common iliac vessels, as assessed on non-contrast-enhanced abdominal computed 121
tomography (CT), were eligible for the study. Exclusion criteria were the presence of 122
multiple ureteral stones, renal insufficiency (estimated glomerular filtration rate below 60 123
ml/min/1.73m2), urinary tract infection, a solitary kidney or pregnancy. Patients with a 124
history of ureteral surgery or previous endoscopic procedures, hypersensitivity to tamsulosin 125
or current alpha-blocker, calcium-antagonist or corticosteroid medication were also excluded. 126
Patient enrolment was performed by the attending urologist.127
Study design: Enrolled patients underwent randomisation in a 1:1 fashion in blocks of 10 to 128
receive either a daily single-dose of tamsulosin (0.4 mg) or placebo. The sequence of 129
randomisation was computer-generated and performed by the university hospital pharmacy 130
using DatInf Randlist software version 1.0 (DatInf GmbH, Tübingen, D). Randomisation data 131
were kept strictly confidential in sealed envelopes, accessible only to the primary and senior 132
investigator. Tamsulosin and placebo were provided by the university hospital pharmacy as 133
gelatine capsules of identical appearance and taste and were presented in identical bottles. 134
Neither the patient nor the attending urologist nor the investigators were aware of study arm 135
assignments until final assessment of outcome. 136
Sample size calculation was performed based on previous reports of spontaneous stone 137
expulsion and assuming a clinically relevant difference in expulsion rate of 25% [13, 16, 17, 138
20]. The stone expulsion rate was estimated to be 90% and 65% for patients with and without 139
tamsulosin medication, respectively. A two group chi-square test with a 0.05 two-sided 140
significance level will have 80% power to detect the difference between a group 1 proportion 141
6of 0.65 and a group 2 proportion of 0.90 when the sample size in each group is 43. Fifty 142
patients per group were finally randomised which allowed for a maximum drop-out rate of 143
14%.144
The study protocol was approved by the local ethics committee and the study was performed 145
in accordance with the Declaration of Helsinki. All enrolled patients provided written 146
informed consent. 147
Intervention: Patients were requested to take the study medication once at the same time 148
each day and to strain their urine. Furthermore, they kept a diary to record the required 149
amount of analgesics, the score of every painful episode on a 10 cm visual analogue scale, 150
the date and time of stone passage and the presence and type of side effects thought to be 151
related to the medication. The study medication was discontinued either after spontaneous 152
stone expulsion, intervention or at the end of the study (i.e. after day 21). After initial 153
analgesia for acute pain management, no regular analgesic medication was maintained. Oral 154
diclophenac (up to 3x50mg) as first-line and oral metamizole (up to 4x1g) as second-line on-155
demand analgesics were prescribed. 156
Follow-up was performed weekly with urinalysis, serum creatinine measurement, abdominal 157
ultrasonography and, in radiopaque stones, plain abdominal x-ray. Low-dose abdominal CT 158
was performed to assess the stone status at the end of the study without knowing the 159
treatment allocation. For patients with a stone-free ureter on final abdominal CT but 160
unnoticed stone expulsion, the date of last positive stone status was recorded. Absence of 161
stone expulsion after day 21 was considered as failed therapy. In these cases, either continued 162
watchful waiting or ureterorenoscopy (URS) or extracorporeal shock-wave lithotripsy 163
(ESWL) was performed. Discontinuation of study medication and intervention before the end 164
of the study due to uncontrollable pain, adverse events, urinary tract infections, acute renal 165
failure or the patient’s desire for stone removal were also considered as failed therapy. These 166
patients were included in the final analysis on an intention to treat basis. Patients who 167
7experienced stone expulsion before first medication, who withdrew their consent or were lost168
to follow-up, were excluded from the analysis. 169
Endpoints: The primary endpoint was the proportion of patients experiencing stone 170
expulsion until day 21, as confirmed by low dose abdominal CT. Secondary endpoints were 171
time to stone passage, the required total amount of analgesics and the reported maximum 172
daily pain-score until stone expulsion, the intervention rate as well as the safety of the 173
therapy. Additionally, factors influencing these endpoints were assessed. 174
Statistical analysis: Statistical analysis was performed using R statistical software (R 175
Foundation for Statistical Computing, Vienna, Austria). Fisher's exact test was used to 176
compare nominal and Mann-Whitney U-test to compare continuous variables between the 177
two treatment arms. Kaplan-Meier estimates were computed for time to stone passage, and 178
compared between the two treatment arms using logrank test. Patients who were able to 179
define the time of stone expulsion were considered events for time to stone passage. Patients 180
with unnoticed stone expulsion were censored at the date of last positive stone status and 181
those who discontinued the therapy were censored at the date of last medication intake. 182
Patients without stone expulsion were censored at day 21. A multiple Cox proportional 183
hazards regression model was generated to assess the predictive value of stone size and 184
location and the prognostic value of therapy, jointly. The significance level in the test for the 185
primary endpoint was set to 0.05. In the exploratory analysis of the secondary endpoints all 186
p-values smaller than 0.05 were considered significant and no correction for multiple testing 187
was performed.188
189
190
Results 191
From September 2006 to September 2008 a total of 100 patients were randomly assigned to 192
the two treatment arms. Overall, 10 patients were excluded from the final analysis (Figure 1). 193
8In 8 cases, treatment was discontinued due to adverse events or uncontrollable pain with 194
subsequent intervention (URS or ESWL). 195
No statistically significant differences were found between the two treatment arms in age, 196
gender, stone size and stone location (Table 1). Median stone size in the entire population 197
was 3.9mm (interquartile range (IQR) 3.5-4.8mm). 198
The spontaneous stone expulsion rate within 21 days was not significantly different between 199
the tamsulosin arm (86.7%) and placebo arm (88.9%; p=1.0). Univariate analyses revealed 200
that neither patients’ gender and age nor left/right location of the stone were predictive 201
factors for stone expulsion. The stone location in the ureter however had a predictive impact 202
on the stone expulsion rate. The spontaneous expulsion of stones at the ureterovesical 203
junction was significantly higher than of stones in the distal part of the ureter (p=0.006). All 204
11 stones which did not pass spontaneously or required treatment before the end of the study 205
were located in the distal part of the ureter. Furthermore, stone size was significantly smaller 206
in the group of patients with spontaneous stone expulsion (p=0.039). The stone expulsion rate 207
was significantly higher for patients with stones of 5mm or smaller compared to patients with 208
stones larger than 5mm (p=0.048). However, the expulsion rate was not significantly 209
different between the treatment arms, neither for patients with stones of 5mm or smaller 210
(p=1.00) nor for those seen with larger stones (p=1.00).211
The Kaplan Meier estimates for time to stone passage are shown in Figure 2. A total of 50 212
patients (56%) were able to define the time of stone expulsion by collecting the stone after 213
urine filtration. Twenty-nine patients (32%) had unnoticed stone expulsion, 8 patients (9%) 214
discontinued the therapy and 3 patients (3%) were not stone-free at the end of the study.215
Median time to stone passage was 7 days (95% CI: 4-13) for patients overall and 7 days 216
(95% CI: 3-10) in the tamsulosin arm and 10 days (95% CI: 3-20) in the placebo arm. The 217
difference between the treatment arms was non-significant (logrank p=0.36). A multiple Cox 218
regression model to analyse predictive factors for time to stone passage revealed only stone 219
9location but not medical therapy or stone size as predictive factors (Table 2). The hazard of 220
expulsion at any time was 3.0-fold higher for stones located at the ureterovesical junction 221
than in the distal part of the ureter.222
The required total amount of analgesics until stone expulsion was significantly different 223
between the two treatment arms (p=0.012). Patients in the tamsulosin arm consumed a 224
median number of 3 (IQR 1-9.8) and patients in the placebo arm a median number of  7 225
analgesics (IQR 4-16) until stone expulsion. Figure 3 shows the course of the medians of the 226
most painful episodes per day. Only the first 10 days were analysed due to the low number of 227
patients being at risk after that day. 228
No severe complications were recorded. Hospital re-admissions with consecutive 229
intervention and discontinuation of the medication were due to uncontrollable pain (7 230
patients) or side effects (1 patient). Six patients (13.3%) in the tamsulosin arm (URS: 4, 231
ESWL: 2) and two (4.4%) in the placebo arm (URS: 1, ESWL: 1) required intervention 232
before the end of the study. This difference was statistically non-significant (p=0.27). None 233
of the patients treated with tamsulosin and three patients (6.7%) treated with placebo failed to 234
expel their stone until day 21. The overall intervention rate was 13.3% in the tamsulosin and 235
8.9% in the placebo arm (p=0.74). 236
Four patients (8.9%) in the tamsulosin arm reported minor side effects. One patient 237
discontinued therapy due to diarrhoea and subsequently was treated by ESWL. One patient238
with a mild cutaneous reaction and two patients with retrograde ejaculation continued 239
therapy. In the placebo arm, one patient (2.2%) reported dizziness and inappetence but 240
continued therapy.241
242
243
244
245
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Discussion246
This first randomised, double-blind and placebo-controlled trial, investigating the efficacy of 247
MET revealed that tamsulosin treatment did not improve the spontaneous expulsion rate of 248
single distal ureteral stones ≤7mm. The proportion of patients experiencing stone expulsion 249
within 21 days was even slightly, but not significantly lower in the tamsulosin arm than in the 250
placebo arm. This finding is in contrast to the results of previous clinical trials which have 251
reported significant improvements of the stone expulsion rate using tamsulosin [10-12, 15]. 252
Two possible reasons have to be highlighted in this context: 1.) The actual stone size and 2.)253
The differences in study design between this and the previous trials.254
Stone size has been identified as an important predictive factor for ureteral stone expulsion 255
[20-22]. The probability for distal ureteral stones to pass spontaneously is as high as 71-98% 256
for stones of 5mm or less and only 25-51% for stones greater than 5mm [20, 23, 24]. 257
Approximately 80% of the stones in the present trial were 5mm or smaller. The actual stone 258
size may be a reason for the high stone expulsion rate in the placebo arm. Yet, it remains 259
unclear if the lack of improvement of the stone expulsion rate in the tamsulosin arm is 260
attributable to the present stone size as well. The majority of stones in the trials reporting a 261
beneficial effect of tamsulosin on the stone expulsion rate were greater than 5mm [10, 12, 15, 262
18]. It is reasonable to presume that the efficacy of MET will be relatively greater for larger 263
stones, as smaller stones are more likely to pass without any treatment. However, currently it 264
is not known whether a potential alpha-blocker effect on stone expulsion depends on ureteral 265
stone size. In the present trial, patients with stones greater than 5mm had a lower chance to 266
pass their stone spontaneously but tamsulosin treatment did not improve the expulsion rate of 267
these stones. Admittedly, the study was not powered for this subgroup analysis and therefore 268
the value of this analysis is limited.269
Three meta-analyses have confirmed a positive effect of alpha-blocker therapy on the stone 270
expulsion rate [25-27]. However, important potential confounders which may affect the 271
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validity of the results and may lead to an over-estimation of the identified treatment effect 272
have also been pointed out [25-28]. Although most of the published studies were randomised, 273
reporting of randomisation methods was often unclear or even absent, as placebo-treatment 274
and blinding to treatment were in general. Furthermore, determination of the stone status by 275
abdominal CT at the end of the study was not performed in most of the previous studies. The 276
differences in study design between the present and previous trials may therefore be an 277
additional factor for the different outcomes. Interestingly, in accordance with the results of 278
the present study, the only other double-blind, placebo-controlled study for alpha-blocker 279
therapy of distal ureteral stones also revealed no improvement in the stone expulsion rate 280
[29]. In this study, the mean stone size was smaller than 5mm as well but the non-subtype-281
selective alpha-1-receptor blocker alfuzosin was investigated. 282
The decision for a conservative medical or an active interventional treatment not only 283
depends on the overall probability of stone expulsion. For many patients, factors like time to 284
convalescence or re-exposure to dreaded colics during conservative treatment have a 285
considerable impact on the decision to opt for an interventional treatment.286
A faster and less painful stone expulsion, irrespective of stone size, has constantly been 287
reported with MET [10, 13, 16]. In the present trial, median time to stone passage was three 288
days shorter for patients treated with tamsulosin than for patients treated with placebo. 289
However, although this difference may be clinically meaningful, it was statistically non-290
significant. 291
The secondary endpoint "total intake of analgesics", however, was significantly different 292
between the treatment arms. Patients in the tamsulosin arm required fewer analgesics until 293
stone expulsion than patients in the placebo arm. This difference may be attributable to the 294
accelerated stone expulsion with a consecutive shorter time at risk for painful events. 295
Additionally, a true analgesic effect of tamsulosin has also been reported [30]. The lower 296
maximum pain scores in the tamsulosin arm already during the first days support the 297
12
existence of such an effect. Thus, pain modulation seems to be an important feature of MET 298
with tamsulosin in patients with stones ≤ 7mm.299
In both treatment arms no serious complications were recorded. Adverse events of tamsulosin 300
treatment were mild and led to therapy discontinuation in one patient only. 301
Some limitations of the present trial deserve mention. The smaller stone size in the present 302
trial compared to previous trials makes it difficult to directly compare the results of the 303
different trials. Furthermore, for 32% of the patients the exact time of stone passage was not 304
available. Thus, they needed to be censored at the last known date of stone presence. 305
Therefore, the secondary end-point “time to stone passage” is based on Kaplan-Meier 306
estimation. 307
308
309
Conclusion:310
Patients with single, distal ureteral stones ≤ 7mm do not benefit from MET with tamsulosin 311
in terms of an improved expulsion rate. Nevertheless, the generally well tolerated treatment 312
may be beneficial for these patients due to an analgesic effect and thus a reduced need of 313
analgesics until stone expulsion.314
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Figure legends:427
428
Figure 1: Trial profile429
430
Figure 2: Kaplan Meier estimates for time to stone passage for the two treatment arms431
432
Figure 3: Median maximum daily pain-score in the two treatment arms. The pain intensity 433
was slightly higher in the placebo arm until day 4. After the fourth day of treatment the 434
differences were marginal.435
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Table 1: Baseline characteristics of 45 patients treated with tamsulosin and 45 treated with 474
placebo. 475
476
477
Tamsulosin Placebo p-value
Age (years) 36 (30-44) 41 (33-54) 0.07
Sex
  male
  female
39 (86.7%)
6 (13.3%)
36 (80%)
9 (20%)
0.57
Stone size (mm) 4.1 (3.5-4.9) 3.8 (3.4-4.3) 0.3
Size distribution  
  < 5mm
  ≥ 5mm
34 (75.6%) 
11 (24.4%)
38 (84.4%)
7 (15.6%)
0.43
Side
  left
  right
18 (40%)
27 (60%)
29 (64.4%)
16 (35.6%)
0.034*
Stone location
  distal
  ureterovesical junction
27 (60%)
18 (40%)
30 (66.7%)
15 (33.3%)
0.66
Data are presented as median (interquartile range) or number (proportion within 
treatment arm).
* indicates a significant difference between the treatment arms. 
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Table 2: Multiple Cox regression analysis for predictive factors for the secondary endpoint 505
“time to stone passage”506
507
508
Variables p-value Hazard ratio 95% confidence interval
Therapy 0.97 0.99 0.55 – 1.79
Stone Location 0.0005 3.17 1.66 – 6.05
Stone size 0.42 0.89 0.66 – 1.19
509
510
511
100 patients enrolled and randomly assigned
50 assigned to tamsulosin 50 assigned to placebo
45 analysed 45 analysed
5 withdrew (not analysed)
2 expulsion before medication
3 lost to follow up
2 discontinuation (analysed)
2 uncontrollable pain / intervention
5 withdrew (not analysed)
2 expulsion before medication
2 withdrew consent
1 lost to follow-up
6 discontinuation (analysed)
5 uncontrollable pain / intervention
1 adverse event
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TAKE HOME MESSAGE
Tamsulosin did not improve the stone expulsion rate of patients with single distal ureteral 
stones ≤ 7mm in this randomised, double-blind, placebo-controlled trial. Nonetheless, patients 
may benefit from a supportive analgesic effect with a reduced need for analgesics. 
*Take Home Message
